Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.41 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | KHK | P50053 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21136632 | 1.00 | MEN1 (0.47) | MEN1KDM4EALDH1A1POLBTP53 | |
| SCHEMBL21135569 | 1.00 | MEN1 (0.47) | MEN1KDM4EALDH1A1POLBTP53 | |
| SCHEMBL31753332 | 0.84 | HRH3 (0.48) | MEN1KDM4EPOLBTP53HRH3 | |
| SCHEMBL9176367 | 0.81 | KDM4E (0.53) | KDM4EPOLBTP53HRH3CHRNA10 | |
| SCHEMBL25855629 | 0.81 | ESR1 (0.45) | POLBMAP4K4KHKJAK2SYK | |
| SCHEMBL21135466 | 0.80 | CYP3A4 (0.56) | KDM4EALDH1A1TP53MAP4K4JAK2 | |
| SCHEMBL21135458 | 0.80 | NOTUM (0.49) | MEN1ALDH1A1MAP4K4JAK2SYK | |
| SCHEMBL7790528 | 0.80 | EPHX2 (0.51) | PIK3CAMTORMAP4K4KHKJAK2 | |
| SCHEMBL77035 | 0.80 | KDM4E (0.49) | MEN1KDM4EALDH1A1POLBTP53 | |
| SCHEMBL14637983 | 0.80 | AR (0.50) | MEN1KDM4EALDH1A1TP53HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3371196-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | UNIV MONTREAL (CA) | 2021-10-27 | — | — | EP | disclosed |
| US-10329307-B2 | Heterocyclic compounds as inhibitors of platelet aggregation | UNIVERSITE DE MONTREAL (CA) | 2019-06-25 | — | — | US | disclosed |
| US-20020193389-A1 | Method of inhibiting neoplastic cells with imidazoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-12-19 | — | — | US | disclosed |
| US-6127541-A | 8-((DISUBSTITUTED AMINO)BENZYLAMINO)-2,3-DIHYDRO-1H-IMIDAZO(4,5-G)QUINAZOLINE-(2-THIONE OR 2-ONE); SELECTIVE CYCLIC GUANOSINE 3',5' MONOPHOSPHATE (CGMP)--SPECIFIC PHOSPHODIESTERASE (PDE) INHIBITORY ACTIVITY | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| EP-0863144-A1 | IMIDAZOQUINAZOLINE DERIVATIVES | Kyowa Hakko Co., Ltd. (JP) | 1998-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329307-B2 | Heterocyclic compounds as inhibitors of platelet aggregation | F12, F2, F3 | MEN1 1966/4885KDM4E 2886/4885ALDH1A1 1559/4885 |
| US-20020193389-A1 | Method of inhibiting neoplastic cells with imidazoquinazoline derivatives | MKI67, HRAS, VHL | MEN1 1099/4885KDM4E 2757/4885ALDH1A1 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.